DLG4 and androgen insensitivity syndrome: Recently, for example, the ESCAPE-NA1 clinical trial found that nerinetide, a neuroprotectant that disrupts excitotoxic post-synaptic density protein 95 (PSD-95), resulted in better functional prognosis and decreased mortality among AIS patients who received mechanical thrombectomy [32].